Buckley Wealth Management LLC purchased a new stake in Becton Dickinson and Co (NYSE:BDX) in the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm purchased 1,421 shares of the medical instruments supplier’s stock, valued at approximately $304,000.

Other large investors have also recently made changes to their positions in the company. Legacy Advisors LLC boosted its holdings in Becton Dickinson and by 7,000.0% in the 4th quarter. Legacy Advisors LLC now owns 497 shares of the medical instruments supplier’s stock valued at $106,000 after purchasing an additional 490 shares during the period. FTB Advisors Inc. boosted its holdings in Becton Dickinson and by 114.2% in the 4th quarter. FTB Advisors Inc. now owns 544 shares of the medical instruments supplier’s stock valued at $116,000 after purchasing an additional 290 shares during the period. Harfst & Associates Inc. boosted its holdings in Becton Dickinson and by 46.4% in the 2nd quarter. Harfst & Associates Inc. now owns 697 shares of the medical instruments supplier’s stock valued at $135,000 after purchasing an additional 221 shares during the period. Exane Derivatives boosted its holdings in Becton Dickinson and by 848.6% in the 4th quarter. Exane Derivatives now owns 702 shares of the medical instruments supplier’s stock valued at $150,000 after purchasing an additional 628 shares during the period. Finally, Meeder Asset Management Inc. bought a new position in Becton Dickinson and in the 4th quarter valued at $160,000. 75.56% of the stock is owned by hedge funds and other institutional investors.

Several research analysts have commented on the stock. Morgan Stanley raised their price target on shares of Becton Dickinson and from $245.00 to $250.00 and gave the company an “equal weight” rating in a report on Wednesday, February 7th. Piper Jaffray Companies reissued an “overweight” rating and issued a $260.00 price target (up from $223.00) on shares of Becton Dickinson and in a report on Tuesday, February 6th. Zacks Investment Research raised shares of Becton Dickinson and from a “hold” rating to a “buy” rating and set a $240.00 price target for the company in a report on Wednesday, January 3rd. Evercore ISI assumed coverage on shares of Becton Dickinson and in a report on Wednesday, January 3rd. They issued an “outperform” rating and a $245.00 price target for the company. Finally, Deutsche Bank set a $260.00 price target on shares of Becton Dickinson and and gave the company a “buy” rating in a report on Friday, December 29th. Four research analysts have rated the stock with a hold rating, twelve have assigned a buy rating and one has given a strong buy rating to the stock. Becton Dickinson and currently has an average rating of “Buy” and a consensus price target of $237.27.

In other news, Director Timothy M. Ring sold 269,661 shares of the firm’s stock in a transaction on Thursday, February 8th. The shares were sold at an average price of $217.82, for a total transaction of $58,737,559.02. Following the sale, the director now owns 295,753 shares in the company, valued at approximately $64,420,918.46. The transaction was disclosed in a filing with the SEC, which is accessible through this link. Company insiders own 1.00% of the company’s stock.

Shares of Becton Dickinson and Co (NYSE:BDX) opened at $218.89 on Tuesday. The company has a current ratio of 1.54, a quick ratio of 0.93 and a debt-to-equity ratio of 1.04. The firm has a market cap of $50,220.00, a price-to-earnings ratio of 167.09, a PEG ratio of 1.49 and a beta of 1.12. Becton Dickinson and Co has a 52-week low of $175.66 and a 52-week high of $248.39.

Becton Dickinson and (NYSE:BDX) last posted its quarterly earnings data on Tuesday, February 6th. The medical instruments supplier reported $2.48 earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of $2.41 by $0.07. The firm had revenue of $3.08 billion for the quarter, compared to analysts’ expectations of $3.05 billion. Becton Dickinson and had a net margin of 2.71% and a return on equity of 16.19%. The business’s quarterly revenue was up 5.4% on a year-over-year basis. During the same quarter last year, the company posted $2.33 EPS. sell-side analysts expect that Becton Dickinson and Co will post 10.95 earnings per share for the current year.

The business also recently disclosed a quarterly dividend, which will be paid on Friday, March 30th. Stockholders of record on Friday, March 9th will be given a dividend of $0.75 per share. This represents a $3.00 annualized dividend and a dividend yield of 1.37%. The ex-dividend date is Thursday, March 8th. Becton Dickinson and’s dividend payout ratio (DPR) is currently 229.01%.

ILLEGAL ACTIVITY WARNING: This piece was first reported by TheOlympiaReport and is the sole property of of TheOlympiaReport. If you are viewing this piece on another website, it was copied illegally and reposted in violation of US and international copyright and trademark laws. The legal version of this piece can be read at https://theolympiareport.com/2018/02/13/buckley-wealth-management-llc-invests-304000-in-becton-dickinson-and-co-bdx-stock.html.

Becton Dickinson and Profile

Becton, Dickinson and Company (BD) is a global medical technology company engaged in the development, manufacture and sale of a range of medical supplies, devices, laboratory equipment and diagnostic products. The Company operates through two segments: BD Medical and BD Life Sciences. The BD Medical segment produces an array of medical technologies and devices that are used to help improve healthcare delivery in a range of settings.

Want to see what other hedge funds are holding BDX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Becton Dickinson and Co (NYSE:BDX).

Institutional Ownership by Quarter for Becton Dickinson and (NYSE:BDX)

Receive News & Ratings for Becton Dickinson and Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Becton Dickinson and and related companies with MarketBeat.com's FREE daily email newsletter.